ClinicalTrials.gg
RecruitingNCT07749924Updated Oct 9, 2026

Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC

An interventional study of Active Surveillance and Adjuvant Intravesical Chemotherapy in Bladder Cancer and Non-Muscle-Invasive Bladder Cancer (NMIBC), sponsored by Tianjin Medical University Second Hospital. Recruiting at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Primary conditionNon-Muscle Invasive Bladder NeoplasmsRegistry: Urinary Bladder NeoplasmsReclassifiedWhy we changed it
Registry
Urinary Bladder Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Non-Muscle Invasive Bladder Neoplasms
Why
  1. The study's listed conditions name Non-Muscle Invasive Bladder Neoplasms, a narrower term within Urinary Bladder Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Tianjin Medical University Second Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 9, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
670
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China — 40 open to participants now, 44 under way, 10 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · China.

Planned enrollment
5th of 47
670 · median 114
Started
2026
with 9 others
No phase
8 of 50
6 open now
Primary completion
2029-03
later than 35 of 43 live
Registered
48th of 50
by date
Lead sponsor
3 of 50
Tianjin Medical University Second Hospital

Among the 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China, this one is the 5th largest by planned enrollment of the 47 interventional ones that give a count, is one of 10 that started in 2026, is one of 8 with no phase, reaches primary completion later than 35 of the 43 other live ones, and was the 48th registered.

Non-Muscle Invasive Bladder Neoplasms

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

40 of the 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Non-Muscle Invasive Bladder Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study will evaluate whether adjuvant intravesical chemotherapy can be safely omitted under active surveillance after complete transurethral resection in selected patients with EAU intermediate-risk non-muscle-invasive bladder cancer.

Patients with intermediate-risk non-muscle-invasive bladder cancer are commonly treated with transurethral resection followed by adjuvant intravesical chemotherapy to reduce the risk of recurrence. However, not all patients may derive the same benefit from additional intravesical treatment. Some tumors may have a low-shedding phenotype, meaning that they show no detectable tumor-associated signals in urine despite the presence of visible bladder tumors.

In this study, preoperative urine-based liquid biopsy will be used to identify patients with a low-shedding profile. This profile is defined by negative results across urine cytology, NMP22, urinary DNA methylation, and urinary tumor DNA testing before transurethral resection.

Eligible patients with EAU intermediate-risk non-muscle-invasive bladder cancer, a negative preoperative urine-based liquid biopsy profile, and complete tumor resection will be randomly assigned to active surveillance or standard adjuvant intravesical chemotherapy. The study will compare recurrence-free survival between the two groups and assess whether active surveillance can avoid immediate intravesical chemotherapy without compromising oncologic safety. Secondary outcomes will include high-grade recurrence, disease progression, need for subsequent bladder cancer treatment, safety, patient-reported outcomes.

03

Conditions studied

  • Bladder Cancer
  • Non-Muscle-Invasive Bladder Cancer (NMIBC)

Browse trials for

Keywords

  • Non-muscle-invasive bladder cancer (NMIBC)
  • Active surveillance
  • Liquid biopsy
04

In context

Non-Muscle Invasive Bladder Neoplasms Reclassified

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

This study's planned enrollment of 670 is above the median of 61 across 232 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Lead sponsor

Tianjin Medical University Second Hospital is the lead sponsor of 60 studies on the registry; 36 are open to participants now.

Compared within Non-Muscle Invasive Bladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urinary Bladder Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. confirmed urothelial carcinoma of the urinary bladder, including tumors with divergent differentiation, provided that the urothelial carcinoma component accounts for >50% of the tumor
  3. Non-muscle-invasive bladder cancer classified as intermediate-risk according to the 2021 European Association of Urology (EAU) NMIBC prognostic risk-group definition. Intermediate-risk disease is defined as NMIBC without concomitant carcinoma in situ that does not meet the criteria for the EAU low-, high-, or very-high-risk groups.
  4. Complete transurethral resection of all visible bladder tumors performed within 6 weeks before randomization, with no macroscopically visible residual disease.
  5. Negative multi-urinary liquid results after complete TURBT and before randomization.
  6. performance status of 0-2.
  7. Adequate clinical condition to undergo protocol-specified intravesical therapy, cystoscopic surveillance, and study-related procedures.
  8. Ability to understand the study requirements and provide written .

Exclusion criteria

Exclusion Criteria:

  1. EAU low-risk, high-risk, or very-high-risk NMIBC.
  2. Any current or previous concomitant carcinoma in situ associated with the qualifying tumor episode.
  3. Muscle-invasive bladder cancer, locally advanced urothelial carcinoma, lymph-node involvement, or urothelial carcinoma.

    Incomplete TURBT, macroscopically visible residual tumor, or inability to achieve complete endoscopic resection before randomization.

  4. Urothelial carcinoma involving the prostatic stroma or prostatic ducts, or carcinoma in situ of the prostatic urethra.
  5. Severe lower urinary tract dysfunction, bladder capacity considered insufficient for intravesical treatment, or another urological condition that may interfere with treatment or outcome assessment.
  6. Another active requiring systemic treatment or likely to interfere with the assessment of study endpoints, except adequately treated non-melanoma skin cancer, localized prostate cancer under surveillance, or another malignancy with a negligible risk of recurrence, as determined by the investigator.
  7. Pregnant or breastfeeding women.
  8. Any serious uncontrolled medical, psychiatric, or social condition that, in the investigator's judgment, would compromise participant safety, protocol adherence, or interpretation of study results.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
670 participants (estimated)

Study arms

  • Experimental
    Active Surveillance

    Participants assigned to this arm will undergo active surveillance after complete transurethral resection of bladder tumor. No adjuvant intravesical chemotherapy will be given. Surveillance will include scheduled cystoscopy, urine cytology, urine-based liquid biopsy testing, and other assessments according to the study protocol. Further diagnostic evaluation or treatment will be performed if recurrence or progression is suspected or confirmed.

    Other: Active Surveillance

  • Active comparator
    Adjuvant Intravesical Chemotherapy

    Participants assigned to this arm will receive one year of adjuvant intravesical chemotherapy after complete transurethral resection of bladder tumor. The preferred agent is gemcitabine; mitomycin C or epirubicin may be used as protocol-allowed alternatives when gemcitabine is unavailable, contraindicated, or not routinely used at the participating center. The planned agent will be specified before randomization. Treatment will consist of an induction course of weekly intravesical instillations followed by maintenance instillations for up to 12 months, according to the study protocol.

    Drug: Adjuvant Intravesical Chemotherapy

Interventions

  • OtherActive Surveillance

    Participants assigned to active surveillance will not receive adjuvant intravesical chemotherapy after complete transurethral resection of bladder tumor. They will undergo scheduled follow-up assessments, including cystoscopy, urine cytology, urine-based liquid biopsy testing, imaging when clinically indicated, and other evaluations according to the study protocol. Further diagnostic evaluation or treatment will be initiated if recurrence or progression is suspected or confirmed.

  • DrugGemcitabineStudies of GemcitabineGemcitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants assigned to this intervention will receive one year of adjuvant intravesical chemotherapy after complete transurethral resection of bladder tumor. Gemcitabine is the preferred protocol-specified agent. Mitomycin C or epirubicin may be used as protocol-allowed alternatives when gemcitabine is unavailable, contraindicated, or not routinely used at the participating center. Treatment will include an induction course followed by maintenance intravesical instillations for up to 12 months.

    Also known as: Gemcitabine, Mitomycin C, Epirubicin

07

What researchers measure

Primary outcomes

  1. Recurrence-free survival

    Recurrence-free survival is defined as the time from randomization to the first histologically confirmed intravesical recurrence or death from any cause, whichever occurs first.

    Time frame: Up to 24 months after randomization

Secondary outcomes

  1. High-grade recurrence-free survival

    High-grade recurrence-free survival is defined as the time from randomization to the first histologically confirmed high-grade intravesical recurrence or death from any cause, whichever occurs first.

    Time frame: Frame: Up to 24 months after randomization

  2. Progression-free survival

    Progression-free survival is defined as the time from randomization to the first occurrence of T1 high-grade disease, carcinoma in situ, muscle-invasive bladder cancer, upper tract urothelial carcinoma, nodal or distant metastasis, radical cystectomy, or death from any cause.

    Time frame: Up to 24 months after randomization

  3. Overall Survival

    Defined as the time from randomization to the date of death from any cause

    Time frame: Up to 24 months after randomization

  4. European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire Core-30 items (EORTC-QLQ-C30) Scores

    EORTC QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. It incorporates 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 symptom scales (fatigue, pain, and nausea or vomiting), and a global health status or HRQoL scale. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity.

    Time frame: Baseline, Weeks 6, 12, 24, 36, and 48

  5. European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire for Non muscle Invasive Bladder Cancer (EORTC-QLQ-NMIBC24) Scores

    EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity.

    Time frame: Baseline, Weeks 6, 12, 24, 36, and 48

  6. EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Scores

    The EQ-5D-5L is a standardized questionnaire used to assess participants' general health status and health-related quality of life. It includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels, ranging from 1 (no problems) to 5 (extreme problems or unable to perform). Responses can be converted into a health utility index score using an appropriate value set, with higher index scores indicating better health status. The EQ-5D-5L also includes a visual analogue scale (EQ VAS), ranging from 0 to 100, where higher scores indicate better self-rated health.

    Time frame: Baseline, Weeks 6, 12, 24, 36, and 48

08

Study locations

5 of 5 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Mar 2029, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2026
First posted
Aug 6, 2026
StartActual
Aug 10, 2026
Primary completionEst.
Mar 1, 2029
CompletionEst.
Mar 1, 2032
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
5 sites changed recruiting status (5 now recruiting)
Show 5 sites
  • Daqing Oil General Hopital · Daqing, Chinano status→Recruiting
  • Nanchang Second People's Hospital · Nanchang, Chinano status→Recruiting
  • The Second Hospital of Tianjin Medical University · Tianjin, Chinano status→Recruiting
  • General Hospital of Tianjin Medical University · Tianjin, Chinano status→Recruiting
  • Tianjin Hospital · Tianjin, Chinano status→Recruiting
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • Daqing Oil General Hopital · Daqing, Chinano status→Recruiting
    • Nanchang Second People's Hospital · Nanchang, Chinano status→Recruiting
    • The Second Hospital of Tianjin Medical University · Tianjin, Chinano status→Recruiting
    • General Hospital of Tianjin Medical University · Tianjin, Chinano status→Recruiting
    • Tianjin Hospital · Tianjin, Chinano status→Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07749924
Lead sponsor
Tianjin Medical University Second Hospital
Responsible party
Sponsor
First posted
Aug 6, 2026
Start date
Aug 10, 2026
Primary completion
Mar 1, 2029 (estimated)
Completion
Mar 1, 2032 (estimated)
Last update
Oct 9, 2026

Study contacts

Hailong Hu, MD
Contact
huhailong@tmu.edu.cn
+8619801518556

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion